National Institutes of Health

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Antimalarial medication, Research, FURI, Congress, Conference, Biotechnology, TIMM, Aspergillosis, GSK, Sale, Mucorales, LAMB, National Institutes of Health, NIH, Trial of the century, IND, AAAM, Investment, Data analysis, Medical Mycology, Pharmaceutical industry

“SCY-247 continues to demonstrate highly encouraging preclinical results, with potent activity against a broad range of fungal pathogens, including mucormycosis.

Key Points: 
  • “SCY-247 continues to demonstrate highly encouraging preclinical results, with potent activity against a broad range of fungal pathogens, including mucormycosis.
  • In March 2023, SCYNEXIS and GSK entered into an exclusive license agreement for the development, manufacturing and commercialization of ibrexafungerp (BREXAFEMME).
  • Presented preclinical data on SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) held in Athens, Greece October 20-23, 2023.
  • Cash, cash equivalents and investments totaled $98.0 million on December 31, 2023, compared to $73.5 million on December 31, 2022.

XORTX Announces New Clinical Advisory Board Member

Retrieved on: 
Wednesday, March 27, 2024
Sanofi, Database, Internal medicine, Critical Path Institute, XRX, TEMPO, Patient, Research, Biomarker, TAME, Polycystic kidney disease, National Institutes of Health, MD, Kidney disease, European Medicines Agency, Publication, PKD, Clinical trial, Boston Medical Center, Therapy, Grady Memorial Hospital, FDA, Food, Pharmaceutical industry

CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease (“ADPKD”), is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board.

Key Points: 
  • CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease (“ADPKD”), is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board.
  • Dr. Allen Davidoff stated, “We are excited that Dr. Ron Perrone has agreed to join XORTX’s Clinical Advisory Board.
  • Dr. Perrone brings substantial medical and professional experience as a thought leader, combined with clinical experience treating patients with ADPKD and kidney disease.
  • We are privileged to have Dr. Perrone join our esteemed Clinical Advisory Board alongside current members, Dr. Petter Bjornstad, Dr. Richard Johnson, Dr. Federico Maese, Dr. Anjay Rostogi and Dr. Charles Edelstein.

C2Sense® and Princeton BioMeditech Receive Second Award from NIH RADx® Tech High Performance Program for Digitally Connected, At-Home Diagnostic Reader and Multiplex COVID-19/Flu A&B Rapid Test

Retrieved on: 
Tuesday, April 9, 2024
Medical imaging, ACME, Halo, Human services, SARS-CoV-2, NIH, Acceleration, Clinical trial, National Institutes of Health, POC, BBC, Omicron, Biological engineering, Bangladesh Technical Education Board, Federal, Health department, PBM, Princeton University

The companies are currently planning their upcoming clinical trial, regulatory submission, and transfer to manufacture.

Key Points: 
  • The companies are currently planning their upcoming clinical trial, regulatory submission, and transfer to manufacture.
  • "After rigorous testing and intensive data collection, Halo®, used in conjunction with the PBM multiplex rapid test, continues to demonstrate outstanding sensitivity and reliability," said Jason Cox, Ph.D., CEO at C2Sense.
  • "Powered by our latest algorithm release, the price vs. performance of our Halo reader is unparalleled."
  • As always, we remain committed to providing our customers with the best possible solution for at-home testing," added Cox.

Guidehouse Honored with Don Strong Community Partner Award for 2024 by George Washington University Milken Institute School of Public Health

Retrieved on: 
Tuesday, April 9, 2024
Employment, Organization, Public health, Veterans' affairs, Partnership, George Washington University, Public, Knowledge, Food and Drug Administration, University, Human services, Doctor of Philosophy, MD, Student, Bangladesh Technical Education Board, National Institutes of Health, Veritas Capital, Public sector, Medicare, Milken Institute, SPH, Consultant, MHA, Food

WASHINGTON, April 9, 2024 /PRNewswire/ -- Guidehouse , a leading global provider of strategy and managed services to commercial and public sector clients, is proud to announce it has been chosen as the recipient of the Don Strong Community Partner Award for 2024 by the George Washington University Milken Institute School of Public Health (SPH).

Key Points: 
  • WASHINGTON, April 9, 2024 /PRNewswire/ -- Guidehouse , a leading global provider of strategy and managed services to commercial and public sector clients, is proud to announce it has been chosen as the recipient of the Don Strong Community Partner Award for 2024 by the George Washington University Milken Institute School of Public Health (SPH).
  • The Don Strong Community Partner Award is presented to organizations that demonstrate exceptional dedication to advancing public health initiatives and promoting the well-being of communities worldwide.
  • Guidehouse received this prestigious recognition in support of its partnership with the Milken Institute SPH, and steadfast support of the school's mission to educate and train future leaders in public health.
  • Guidehouse was celebrated at the Community Partner Appreciation Event on April 4 at the Milken Institute SPH.

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Retrieved on: 
Monday, March 18, 2024
Department of Defence, Food and Drug Administration, Burn, Learning, Patient, BVA, Sale, Nature, Statistics, Investment, Note, LVAD, ICU, Duke, Form, Blood volume, NIH, Heart failure, Length of stay, American College, Operation, Hand, Health, Food, Sepsis, Acceleration, Letter, Proxy, Knowledge, Research, Hospital, Acquisition, CLIA, Clinical study design, Family, FDA, Consultant, Annual general meeting, Diagnosis, RCT, Financial statement, Growth, Syncope, Mortality, National Institutes of Health, Nursing care plan, Bangladesh Technical Education Board, Net, Government, Physician, Medicine, Pharmaceutical industry

We have never been more focused on our mission and goals. Every team member at Daxor sees both the remarkable strides the company has made over the past year solidifying its position as the global leader in blood volume measurement technology and the promise of what our rapid expansion means for both the company and the tens of millions of patients whose care we are eager to significantly improve. In every area 2023 and the strong start of 2024 has shown substantial progress for the company -- in revenue growth, new customer acquisitions, increasing utilization of our products by existing customers, next generation systems completed and under Food and Drug Administration (FDA) review, positive clinical studies, new patents granted and pending, successful National Institutes of Health (NIH) grant awards, Department of Defense (DoD) contracts awarded, and further research and development for groundbreaking products set to launch in subsequent fiscal years. I will detail below more in these areas but first wish to review why our company’s mission to commercialize the products that enable optimal patient care is so vital.

Key Points: 
  • Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh.
  • Many of these markers are costly, some are invasive, and none are accurate – in contrast to Daxor’s proven 98% accurate system.
  • Care teams cannot effectively treat what they do not correctly diagnose, so our rapid accurate diagnostic test is a game-changer.
  • Daxor has been reporting as an investment company under the Investment Company Act of 1940 since January 1, 2012.

Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Retrieved on: 
Monday, March 18, 2024
Letter, Form, Research, Sale, NAV, Annual report, National Institutes of Health, Bangladesh Technical Education Board, FDA, Cryptocurrency

Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2023.

Key Points: 
  • Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2023.
  • Management reported a NAV of $7.08 per share for fiscal 2023 versus $6.75 for the comparable period in 2022.
  • Management forecasts break-even for the operating company within 12-months if anticipated next generation units are cleared by FDA for sale, new contracts, and sales growth continues.
  • “We are pleased with our strong financial performance for fiscal 2023 driven by a combination of sold, leased, placed devices for commercial and research uses, and new lab services accounts, with eighteen new clients added.

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Retrieved on: 
Wednesday, March 13, 2024
Gram-negative bacteria, Department of Defence, Urinary tract infection, GSK, Patient, Human services, Quality of life, IND, Tebipenem, Clinical trial, Therapy, Infection, Research, Policy, Treasurer, Carbapenem-resistant enterobacteriaceae, Safety, Pharmacokinetics, Federal, Food, AP, Drug discovery, Disease, Kidney, SPA, Acinetobacter baumannii, MDR, Pyelonephritis, Annual report, FDA, Army, HBR, Government, Unitary state, NTM, Assistant, Fungal infection, Pseudomonas aeruginosa, Hope, National Institutes of Health, ID, Mycobacterium avium complex, Bangladesh Technical Education Board, Administration, Pharmaceutical industry

“2023 was a productive year for Spero and we have been focused on execution across our programs,” said Sath Shukla, President, and Chief Executive Officer of Spero.

Key Points: 
  • “2023 was a productive year for Spero and we have been focused on execution across our programs,” said Sath Shukla, President, and Chief Executive Officer of Spero.
  • Top-line data from the Phase 2a proof-of-concept clinical trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients is expected in 2H 2024.
  • Spero commenced enrollment in PIVOT-PO, a global, randomized, double-blind, Phase 3 clinical trial of tebipenem HBr in patients with cUTI, including AP in December 2023.
  • Total revenue for the fourth quarter of 2023 was $73.5 million, compared with total revenue of $47.4 million for the fourth quarter of 2022.

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer

Retrieved on: 
Monday, April 1, 2024
Research, Genetics, Clinical Trials, Biotechnology, Biometrics, Health, Pharmaceutical, Science, Oncology, NCI, Checkmate, Hematology, Immunotherapy, Cystectomy, Colorectal cancer, Patient, DNA, National Cancer Institute, Nature, Bladder cancer, MD, Medicine, NTRA, National Institutes of Health, Nivolumab, MRD, Safety, Bangladesh Technical Education Board, Multimedia, Recurrence, FDA, Transitional epithelium, PD-1, Medical imaging

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and the Alliance for Clinical Trials in Oncology, which is part of the National Clinical Trials Network (NCTN) funded by the National Cancer Institute (NCI), part of National Institutes of Health, today announced the launch of Alliance A032103 ( MODERN ), a randomized, phase II/III, biomarker-integrated trial.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and the Alliance for Clinical Trials in Oncology, which is part of the National Clinical Trials Network (NCTN) funded by the National Cancer Institute (NCI), part of National Institutes of Health, today announced the launch of Alliance A032103 ( MODERN ), a randomized, phase II/III, biomarker-integrated trial.
  • Alliance A032103 (MODERN) will utilize Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test, to help guide personalized treatment based on molecular status in patients diagnosed with muscle-invasive urothelial cancer (MIUC) after radical cystectomy.
  • Patients will be divided into two cohorts based on an initial assessment of MRD status.
  • “We are grateful to collaborate with the Alliance on this important study.”

ATCC Announces Award from the National Cancer Institute to Provide Biospecimen Processing Services and Assays for Cancer Research

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Health, Oncology, Clinical Trials, NCI, BAAS, Research, HHS, National Cancer Institute, Cancer, Doctor of Philosophy, IDIQ, NIH, MBA, PMP, National Institutes of Health, Division, Bangladesh Technical Education Board, Collection, Federal, Federation

This task order, 75N91022D0002.75N91024F00001, under the Division of Cancer Epidemiology and Genetics (DCEG) Field and Biospecimen Support Services’ Multiple Award Indefinite Delivery/Indefinite Quantity (IDIQ), will assist the DCEG’s Biospecimen Activity and Assay Support (BAAS) program by providing biospecimen processing services, as well as molecular and genetic assays, for epidemiologic and clinical cancer research studies.

Key Points: 
  • This task order, 75N91022D0002.75N91024F00001, under the Division of Cancer Epidemiology and Genetics (DCEG) Field and Biospecimen Support Services’ Multiple Award Indefinite Delivery/Indefinite Quantity (IDIQ), will assist the DCEG’s Biospecimen Activity and Assay Support (BAAS) program by providing biospecimen processing services, as well as molecular and genetic assays, for epidemiologic and clinical cancer research studies.
  • “For more than a decade, we have been supporting researchers within the DCEG community by supplying the high-quality biospecimen processing services they need to achieve results and scientific breakthroughs,” said ATCC chairman and CEO Raymond H. Cypess, DVM, PhD.
  • “At ATCC, we offer credible high-quality clinical services that support complex research,” said Rebecca Bradford , MBA, MS, PMP, vice president of Government Programs within ATCC Federal Solutions .
  • “With this new DCEG contract, we continue to provide innovative solutions to support its Biospecimen Activity and Assay Support program.”

USA Patient Registry Software Market Outlook to 2028, Featuring IQVIA, Optum (UnitedHealth Group), Phytel, Dacima Software, FIGmd, Syapse and Pharos Innovations - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Research, Software, University, Infectious Diseases, Education, Hospitals, Health Technology, Genetics, Health Insurance, Data Management, Science, Technology, Clinical Trials, Biotechnology, FDA, Insurance, Health, Professional Services, IOT (Internet of Things), Data Analytics, White House, Federal Government, Practice Management, Managed Care, Other Health, Public Policy, Government, Pharmaceutical, Other Science, Pancreatic disease, Consolidated, Patient, Conditional sentence, Optum, Health information management, Food and Drug Administration, Geography, NPF, RWE, Internet of things, Openclinica, DNA, Policy, Electronic health record, NIH, City, Privacy, CMS, Food, Organization, Prevalence, Federation, Internet, Cancer, Drug development, IQVIA, Evidence-based medicine, RDCRN, Type, Data science, Caregiver, Public health surveillance, Government agency, Registry, EHR, CDC, National Institutes of Health, Bangladesh Technical Education Board, Medicare, Collection, Medical device

The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.

Key Points: 
  • The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.
  • Patient registry software could facilitate data sharing and analysis among these entities, leading to increased adoption
    The patient registry software market in the USA is a part of the broader healthcare information technology sector.
  • Key players in the USA patient registry software market includes IQVIA, Dacima Software, OpenClinica, FIGmd, Dendrite Clinical Systems and various universities conducting medical clinical studies.
  • As technology & data science continue to evolve, the patient registry software market is likely to incorporate more advanced analytics techniques.